Brief: Bio-Path Holdings Provides Clinical Update And Expansion Plans
08/07/2024 13:11
July 8 (Reuters) - Bio Path Holdings Inc BPTH.O :
* BIO-PATH HOLDINGS PROVIDES CLINICAL UPDATE AND EXPANSION
PLANS
* BIO PATH HOLDINGS INC: MARKS MEANINGFUL PROGRESS ACROSS
KEY
CLINICAL TRIALS IN MULTIPLE CANCER INDICATIONS
* BIO PATH HOLDINGS : PREXIGEBERSEN PHASE 2 CLINICAL TRIAL
CURRENTLY PAUSED FOR INTERIM ANALYSIS, AMENDMENT PREPARATION,
FDA REVIEW
Source text for Eikon: ID:nGNXbL8Nvf
Further company coverage: BPTH.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Bio Path Holdings
See all newsBrief: Bio-Path Holdings Seeks Financing For Turnaround & Strategic Actions
Brief: Bio-Path Holdings Reports Full Year 2024 Financial Results
Brief: Bio-Path Holdings Announces Pre-Clinical Results Signaling Increased Potential for BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients
Brief: Bio-Path Provides Key Clinical Updates
Brief: Bio-Path Holdings Provides Update From Phase 1/1B Clinical Trial Of Bp1002 For Treatment Of Refractory/Relapsed Acute Myeloid Leukemia